KR20140003316A - 증식성 질환의 치료 - Google Patents

증식성 질환의 치료 Download PDF

Info

Publication number
KR20140003316A
KR20140003316A KR1020127032033A KR20127032033A KR20140003316A KR 20140003316 A KR20140003316 A KR 20140003316A KR 1020127032033 A KR1020127032033 A KR 1020127032033A KR 20127032033 A KR20127032033 A KR 20127032033A KR 20140003316 A KR20140003316 A KR 20140003316A
Authority
KR
South Korea
Prior art keywords
seq
cancer
plant
nad1
defensin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127032033A
Other languages
English (en)
Korean (ko)
Inventor
마크 데런 휴렛
이반 카 호 푼
마릴린 앤 앤더슨
Original Assignee
발모럴 오스트레일리아 피티와이 리미티드
헥시마 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 발모럴 오스트레일리아 피티와이 리미티드, 헥시마 리미티드 filed Critical 발모럴 오스트레일리아 피티와이 리미티드
Publication of KR20140003316A publication Critical patent/KR20140003316A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
KR1020127032033A 2010-06-24 2011-06-23 증식성 질환의 치료 Withdrawn KR20140003316A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35812610P 2010-06-24 2010-06-24
US61/358,126 2010-06-24
PCT/AU2011/000760 WO2011160174A1 (en) 2010-06-24 2011-06-23 Treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
KR20140003316A true KR20140003316A (ko) 2014-01-09

Family

ID=45370753

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127032033A Withdrawn KR20140003316A (ko) 2010-06-24 2011-06-23 증식성 질환의 치료

Country Status (12)

Country Link
US (1) US20120172313A1 (https=)
EP (1) EP2585095A4 (https=)
JP (1) JP2013530965A (https=)
KR (1) KR20140003316A (https=)
CN (1) CN103037888A (https=)
AU (1) AU2011269726B2 (https=)
CA (1) CA2803027A1 (https=)
MX (1) MX2012014711A (https=)
NZ (1) NZ603442A (https=)
SG (1) SG186385A1 (https=)
WO (1) WO2011160174A1 (https=)
ZA (1) ZA201208389B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2825118C (en) 2011-02-07 2020-02-18 Hexima Limited Modified plant defensins useful as anti-pathogenic agents
WO2013039861A2 (en) * 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2851144A1 (en) * 2011-10-19 2013-04-25 Hexima Limited Novel plant defensins and use in the treatment of proliferative diseases
SG11201708815UA (en) * 2015-05-29 2017-12-28 Hexima Ltd A method of in vivo treatment
CN111751345A (zh) * 2020-07-08 2020-10-09 深圳海关动植物检验检疫技术中心 一种苜蓿黄萎病菌活性检测方法
KR102371762B1 (ko) * 2020-12-29 2022-03-07 중앙대학교 산학협력단 Brca1 매개 nsd2 유비퀴틴화를 통한 세포 분화 및 세포사멸 조절 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60124000T2 (de) * 2000-08-25 2007-06-28 Basf Plant Science Gmbh Neuartige, für na+/h+ antiporter kodierende pflanzliche polynukleotide
ATE510015T1 (de) * 2001-02-08 2011-06-15 Hexima Ltd Aus pflanzen stammende moleküle und diese codierende genetische sequenzen sowie verwendungen dafür
US20070207209A1 (en) * 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
US20100095408A1 (en) * 2008-08-05 2010-04-15 Hexima Limited Anti-Pathogen Systems

Also Published As

Publication number Publication date
SG186385A1 (en) 2013-01-30
JP2013530965A (ja) 2013-08-01
AU2011269726B2 (en) 2013-11-28
CN103037888A (zh) 2013-04-10
NZ603442A (en) 2013-09-27
MX2012014711A (es) 2013-03-21
EP2585095A1 (en) 2013-05-01
AU2011269726A1 (en) 2012-11-29
ZA201208389B (en) 2013-06-26
CA2803027A1 (en) 2011-12-29
WO2011160174A1 (en) 2011-12-29
EP2585095A4 (en) 2013-11-13
US20120172313A1 (en) 2012-07-05

Similar Documents

Publication Publication Date Title
KR20140003316A (ko) 증식성 질환의 치료
Lay et al. Defensins-components of the innate immune system in plants
Brand et al. Novel dermaseptins from Phyllomedusa hypochondrialis (Amphibia)
Petersen et al. Peanut defensins: Novel allergens isolated from lipophilic peanut extract
Kim et al. In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines
Mackintosh et al. A gloverin-like antibacterial protein is synthesized in Helicoverpa armigera following bacterial challenge
CN107529761B (zh) 使用台湾假单孢菌控制昆虫及微生物的组合物及方法
Wang et al. A multigene family of Heteractis magnificalysins (HMgs)
Wang et al. Involvement of a pattern recognition receptor C-type lectin 7 in enhancing cellular encapsulation and melanization due to its carboxyl-terminal CRD domain in the cotton bollworm, Helicoverpa armigera
Zottich et al. An antifungal peptide from Coffea canephora seeds with sequence homology to glycine-rich proteins exerts membrane permeabilization and nuclear localization in fungi
Chang et al. IbACP, a sixteen-amino-acid peptide isolated from Ipomoea batatas leaves, induces carcinoma cell apoptosis
US9540423B2 (en) Plant defensins and use in the treatment of proliferative diseases
Montesinos et al. Antimicrobial peptides for plant disease control. From discovery to application
Liu et al. A novel junctional adhesion molecule A (CgJAM-AL) from oyster (Crassostrea gigas) functions as pattern recognition receptor and opsonin
Zhang et al. A survey of the venom of the spider Lycosa vittata by biochemical, pharmacological and transcriptomic analyses
Zhu et al. Leureptin: a soluble, extracellular leucine-rich repeat protein from Manduca sexta that binds lipopolysaccharide
Xu et al. Eukaryotic expression and antimicrobial spectrum determination of the peptide tachyplesin II
Conlon et al. Peptidomic analysis of skin secretions of the Mexican burrowing toad Rhinophrynus dorsalis (Rhinophrynidae): Insight into the origin of host-defense peptides within the Pipidae and characterization of a proline-arginine-rich peptide
WO2013062444A1 (en) Peptide azemiopsin selectively interacting with nicotinic acetylcholine receptors of muscle type
Lee et al. Functional characterization of pathogen-responsive protein AtDabb1 with an antifungal activity from Arabidopsis thaliana
NZ622284B2 (en) Novel plant defensins and use in the treatment of proliferative diseases
Kaas et al. Antimicrobial peptides in plants.
Barkhuizen Mode of action studies of defensin peptides from native South African Brassicaceae species
Kumari Discovery and application of cysteine-rich peptides from medicinal plants in drug development
ELAYAPERUMAL Purification and characterization of antimicrobial peptide present in the gill epidermal mucoprotein of upeneus vittatus (forsskal, 1775).

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20121206

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid